Horizon Pharma PLC (HZNP)

12.32
NASDAQ : Health Care
Prev Close 12.27
Day Low/High 12.12 / 12.44
52 Wk Low/High 9.45 / 21.98
Avg Volume 3.62M
Exchange NASDAQ
Shares Outstanding 163.35M
Market Cap 2.00B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Scores Ninth Straight Record Close With Tiny Gains, S&P 500 at All-Time High

Dow Scores Ninth Straight Record Close With Tiny Gains, S&P 500 at All-Time High

DJIA, S&P 500 and Nasdaq all rise slightly on the session.

Dow Is Back on Track to Close at a Record High as Consumer Staples Lead

Dow Is Back on Track to Close at a Record High as Consumer Staples Lead

The Dow has closed with a record for eight straight days. It's going for its ninth.

Energy Losses Put Dow's Record-Breaking Streak in Jeopardy

Energy Losses Put Dow's Record-Breaking Streak in Jeopardy

The Dow could close with its ninth day of records.

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher

Horizon Pharma, Mylan and Intellia Therapeutics were among the biotech stock movers in premarket trading on Aug. 7.

Stock Futures Rise as Dow Shoots for Its Ninth Straight Day of Records

Stock Futures Rise as Dow Shoots for Its Ninth Straight Day of Records

Stock futures are higher.

Horizon Pharma Stock Sees Short Interest Expand By 18.7%

The most recent short interest data has been released for the 07/14/2017 settlement date, which shows a 2,838,341 share increase in total short interest for Horizon Pharma plc , to 17,983,730, an increase of 18.74% since 06/30/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Horizon Pharma Plc Announces Four Poster Presentations On PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules At Cystinosis Research Network 2017 Family Conference

Horizon Pharma Plc Announces Four Poster Presentations On PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules At Cystinosis Research Network 2017 Family Conference

-- In a New Study Comparing PROCYSBI and Immediate-Release Cysteamine, Those Treated with PROCYSBI Had a 26 Percent Reduction in Exhaled Dimethyl Sulphide, Which is Associated with Halitosis --

Horizon Pharma Plc Announces District Court Decision To Uphold VIMOVO® (naproxen/esomeprazole Magnesium) Patents

Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories, Mylan, and Lupin

Epidemiologic Study Findings Show Over 400 Percent Increase In Gout Patient Hospitalizations Since 1993

Study Findings Underscore Burden of Gout on Patients and Healthcare System and Need for Improved Disease Management

5 Stocks Setting Up for Big Breakouts

5 Stocks Setting Up for Big Breakouts

Here's how to potentially rake in some fat profits off a number of hot breakout setups.

Short Interest In Horizon Pharma Falls 11.2%

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 1,518,745 share decrease in total short interest for Horizon Pharma plc , to 12,055,991, a decrease of 11.19% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Horizon Pharma Plc Announces District Court Decision To Uphold PENNSAID® (diclofenac Sodium Topical Solution) 2% W/w Patent

Patent Covering PENNSAID® 2% Infringed by a Proposed Generic Developed by Actavis Laboratories UT, Inc.

Short Interest In Horizon Pharma Jumps 10%

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 1,239,832 share increase in total short interest for Horizon Pharma plc , to 13,574,736, an increase of 10.05% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Closing Bell: Volatility at Lowest Since 1993; Pershing Backs Howard Hughes

Closing Bell: Volatility at Lowest Since 1993; Pershing Backs Howard Hughes

Volatility sank to its lowest level since 1993 to begin the new week as indexes held close to their flatlines.

TheStreet Quant Rating: D (Sell)